Page 115 - 202014
P. 115
hypertension[J]. Clin Pulm Med，2017，24（4）：149-159. analysis[J]. Can Respir J，2005，12（8）：419-425.
[15] WANG S，YU M，ZHENG X，et al. A Bayesian network [22] GARIN MC，CLAR KL，CHUMNEY EC，et al. Cost-utili-
meta-analysis on the efficacy and safety of eighteen target- ty of treatments for pulmonary arterial hypertension a mar-
ed drugs or drug combinations for pulmonary arterial hy- kov state-transition decision analysis model[J]. Clin Drug
pertension[J]. Drug Deliv，2018，25（1）：1898-1909. Invest，2009，29（10）：635-646.
[16] PICKEN C，FRAGKOS KC，EDDAMA M. Adverse events [23] ROMAN A，BARBERÀ JA，ESCRIBANO P，et al. Cost
of prostacyclin mimetics in pulmonary arterial hyperten- effectiveness of prostacyclins in pulmonary arterial hyper-
sion：a systematic review and meta-analysis[J]. J Clin tension[J]. Appl Health Econ Health Policy，2012，10（3）：
Med，2019. DOI：10.3390/jcm8040481. 175-188.
[17] PETROVIČ M，LOCATELLI I. A Bayesian network me- [24] INAHTA. INAHTA HTA Checklist English[EB/OL].（2007-
ta-analysis of add-on drug therapies specific for pulmo- 05）[2020-06-01]. http：//www.inahta.org/wp-content/up-
nary arterial hypertension[J]. Ann Pharmacother，2020，54 loads/2014/04/INAHTA_HTA_Checklist_English.pdf
（4）：423-433. [25] 王冬，许锋.卫生技术评估在医院层面的应用[J].中国医
[18] PETROVIČ M，LOCATELLI I. Comparative effective- 学装备，2017，14（11）：147-149.
ness of pulmonary arterial hypertension drugs in treat- [26] SHEA BJ，REEVES BC，WELLS GA，et al. AMSTAR 2：
ment-naive patients：a network meta-analysis[J]. J Comp a critical appraisal tool for systematic reviews that include
Eff Res，2020，9（1）：7-22. randomised or non-randomised studies of healthcare inter-
[19] HIGHLAND KB，STRANGE C，MAZUR J，et al. Treat- ventions，or both[J]. BMC，2017. DOI：10.1136/bmj.j4008.
ment of pulmonary arterial hypertension：a preliminary de- [27] HUSEREAU D，DRUMMOND M，PETROU S，et al.
cision analysis[J]. Chest，2003，124（6）：2087-2092. Consolidated Health Economic Evaluation Reporting Stan-
[20] NARINE L，HAGUE LK，WALKER JH，et al. Cost-mini- dards（CHEERS）statement[J]. BMJ，2013. DOI：10.1186/
mization analysis of treprostinil vs. epoprostenol as an al- 1478-7547-11-6.
ternate to oral therapy non-responders for the treatment of [28] WATT A，ALUN C，LANA S，et al. Rapid reviews versus
pulmonary arterial hypertension[J]. Curr Med Res Opin， full systematic reviews：an inventory of current methods
2005，21（12）：2007-2016. and practice in health technology assessment[J]. Int J
[21] EINARSON TR，GRANTON JT，VICENTE C，et al. Technol Assess Health Care，2008，24（2）：133-139.
Cost-effectiveness of treprostinil versus epoprostenol in （收稿日期：2020-04-10 修回日期：2020-06-15）
patients with pulmonary arterial hypertension：a Canadian （编辑：孙 冰）
《中国药房》杂志——中国科技论文统计源期刊，欢迎投稿、订阅
中国药房 2020年第31卷第14期 China Pharmacy 2020 Vol. 31 No. 14 ·1769 ·
